285 related articles for article (PubMed ID: 24434424)
1. Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.
Paoli EE; Ingham ES; Zhang H; Mahakian LM; Fite BZ; Gagnon MK; Tam S; Kheirolomoom A; Cardiff RD; Ferrara KW
J Control Release; 2014 Mar; 178():108-17. PubMed ID: 24434424
[TBL] [Abstract][Full Text] [Related]
2. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.
Grange C; Geninatti-Crich S; Esposito G; Alberti D; Tei L; Bussolati B; Aime S; Camussi G
Cancer Res; 2010 Mar; 70(6):2180-90. PubMed ID: 20215497
[TBL] [Abstract][Full Text] [Related]
3. Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
Rizzitelli S; Giustetto P; Cutrin JC; Delli Castelli D; Boffa C; Ruzza M; Menchise V; Molinari F; Aime S; Terreno E
J Control Release; 2015 Mar; 202():21-30. PubMed ID: 25626083
[TBL] [Abstract][Full Text] [Related]
4. Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance.
de Smet M; Langereis S; van den Bosch S; Grüll H
J Control Release; 2010 Apr; 143(1):120-7. PubMed ID: 19969035
[TBL] [Abstract][Full Text] [Related]
5. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature.
Herringson TP; Altin JG
Int J Pharm; 2011 Jun; 411(1-2):206-14. PubMed ID: 21443937
[TBL] [Abstract][Full Text] [Related]
6. The release of Doxorubicin from liposomes monitored by MRI and triggered by a combination of US stimuli led to a complete tumor regression in a breast cancer mouse model.
Rizzitelli S; Giustetto P; Faletto D; Delli Castelli D; Aime S; Terreno E
J Control Release; 2016 May; 230():57-63. PubMed ID: 27049069
[TBL] [Abstract][Full Text] [Related]
7. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
Gray BP; McGuire MJ; Brown KC
PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
[TBL] [Abstract][Full Text] [Related]
8. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
9. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
Zhao C; Feng Q; Dou Z; Yuan W; Sui C; Zhang X; Xia G; Sun H; Ma J
PLoS One; 2013; 8(9):e73860. PubMed ID: 24040096
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
11. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery.
Park JH; Cho HJ; Yoon HY; Yoon IS; Ko SH; Shim JS; Cho JH; Park JH; Kim K; Kwon IC; Kim DD
J Control Release; 2014 Jan; 174():98-108. PubMed ID: 24280260
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin.
Fite BZ; Kheirolomoom A; Foiret JL; Seo JW; Mahakian LM; Ingham ES; Tam SM; Borowsky AD; Curry FE; Ferrara KW
J Control Release; 2017 Jun; 256():203-213. PubMed ID: 28395970
[TBL] [Abstract][Full Text] [Related]
14. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
16. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.
Yang B
Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868
[TBL] [Abstract][Full Text] [Related]
17. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.
Li L; ten Hagen TL; Hossann M; Süss R; van Rhoon GC; Eggermont AM; Haemmerich D; Koning GA
J Control Release; 2013 Jun; 168(2):142-50. PubMed ID: 23524188
[TBL] [Abstract][Full Text] [Related]
18. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
19. DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.
Camacho KM; Menegatti S; Vogus DR; Pusuluri A; Fuchs Z; Jarvis M; Zakrewsky M; Evans MA; Chen R; Mitragotri S
J Control Release; 2016 May; 229():154-162. PubMed ID: 27034194
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
